EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care

Amanda Roberts, Julie Hallet, Lena Nguyen, Natalie Coburn, Frances C Wright, Sonal Gandhi, Katarzyna Jerzak, Andrea Eisen, Nicole J Look Hong

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07282-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Amanda Roberts und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. amanda.roberts@sunnybrook.ca. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Erb-b2 Receptor Tyrosine Kinases, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Institute for Clinical Evaluative Sciences, Canadian Cancer Society, Sunnybrook Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Neoadjuvant chemotherapy (NAC) for triple-negative (TN) and Her2-positive (HER2) breast cancers is supported by international guidelines as it can decrease extent of surgery, provide prognostic information, and allow response-driven adjuvant therapies. Our goal was to describe practice patterns for patients with TN and HER2-positive breast cancer and identify the factors associated with the receipt of NAC versus surgery as initial treatment. METHODS: A retrospective population-based cohort study of adult women diagnosed with stage I-III TN or HER2-positive breast cancer (2012-2020) in Ontario was completed using linked administrative datasets. The primary outcome was NAC as first treatment. The association between NAC and patient, tumor, and practice-related factors was examined using multivariable logistic regression models. RESULTS: Of 14,653 patients included, 23.9% (n = 3500) underwent NAC as first treatment. Patients who underwent NAC were more likely to be younger and have larger tumors, node-positive disease, and stage 3 disease. Of patients who underwent surgery first, 8.8% were seen by a medical oncologist prior to surgery. On multivariable analysis, increasing tumor size (T2 vs T1/T0: 2.75 (2.31-3.28)) and node-positive (N1 vs N0: OR 3.54 (2.92-4.30)) disease were both associated increased odds of receiving NAC. CONCLUSION: A considerable proportion of patients with TN and HER2-positive breast cancer do not receive NAC as first treatment. Of those, most were not assessed by both a surgeon and medical oncologist prior to initiating therapy. This points toward potential gaps in multidisciplinary assessment and disparities in receipt of guideline-concordant care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesTriple Negative Breast NeoplasmsHumansFemaleMiddle AgedRetrospective StudiesAdultAgedStandard of CareChemotherapy, AdjuvantOntarioAntineoplastic Combined Chemotherapy ProtocolsNeoplasm StagingPrognosisBreast Neoplasms

Stichwörter der Autor:innen

BreastChemotherapyHer2 positiveNeoadjuvantTriple negative

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. amanda.roberts@sunnybrook.ca.
  • Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada. amanda.roberts@sunnybrook.ca.
  • Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada.
  • ICES, Toronto, ON, Canada.
  • Department of Medicine, Sunnybrook Health Science Centre, Toronto, ON, Canada.

Förderung

  • Institute for Clinical Evaluative Sciences
  • Canadian Cancer Society
  • Sunnybrook Research Institute

Zitieren

APA

Roberts, A., Hallet, J., Nguyen, L., Coburn, N., Wright, F. C., Gandhi, S., Jerzak, K., Eisen, A., & Look Hong, N. J. (2024). Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07282-1

Vancouver

Roberts A, Hallet J, Nguyen L, Coburn N, Wright FC, Gandhi S, et al. Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07282-1

BibTeX
@article{Roberts2024,
  author = {Roberts, Amanda and Hallet, Julie and Nguyen, Lena and Coburn, Natalie and Wright, Frances C and Gandhi, Sonal and Jerzak, Katarzyna and Eisen, Andrea and Look Hong, Nicole J},
  title = {Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07282-1}
}
Kostenlos starten →